A New Regime Takes The Reins At Teva

 
• By Jessica Merrill

New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.

sales manager giving advice to his couple clients

More from Leadership

More from Generics Bulletin